May 9 (Reuters) - Quest Pharmatech Inc QPT.V :
* Oncoquest announces enrollment of first patient in phase 1/2 clinical study using combination of oregovomab with checkpoint inhibitor nivolumab in recurrent ovarian cancer Source text for Eikon: ID:nPn2qSB7ha Further company coverage: QPT.V